Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375 Patel, 2013, J Clin Oncol, 31, 4349, 10.1200/JCO.2012.47.9626 Reck, 2009, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466 Paz-Ares, 2013, PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer, J Clin Oncol, 31, 2895, 10.1200/JCO.2012.47.1102 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Gettinger, 2015, Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, 33, 2004, 10.1200/JCO.2014.58.3708 Okazaki, 2013, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application, Nat Immunol, 14, 1212, 10.1038/ni.2762 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428 Hodi, 2016, Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, Lancet Oncol, 17, 1558, 10.1016/S1470-2045(16)30366-7 Gettinger, 2016, Nivolumab monotherapy for first-line treatment of advanced non-small cell lung cancer, J Clin Oncol, 34, 2980, 10.1200/JCO.2016.66.9929 Rizvi, 2016, Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer, J Clin Oncol, 34, 2969, 10.1200/JCO.2016.66.9861 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Phillips, 2015, Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer, Appl Immunohistochem Mol Morphol, 23, 541, 10.1097/PAI.0000000000000256 Antonia, 2014, Safety and efficacy of first-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC), Int J Radiat Oncol Biol Phys, 90, S32, 10.1016/j.ijrobp.2014.08.207 Rizvi, 2015, Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC), J Thorac Oncol, 10, S176 Govindan, 2012, Genomic landscape of non-small cell lung cancer in smokers and never-smokers, Cell, 150, 1121, 10.1016/j.cell.2012.08.024 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369 Antonia, 2016, Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, Lancet Oncol, 17, 883, 10.1016/S1470-2045(16)30098-5 Hammers, 2015, Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC), J Clin Oncol, 33 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 10.1056/NEJMoa1606774 Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, Lancet Oncol, 17, 299, 10.1016/S1470-2045(15)00544-6 Gadgeel, 2016, Pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C, J Clin Oncol, 34 Liu, 2015, Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), J Clin Oncol, 33